Liver cirrhosis
Long considered to be permanent, the extensive scarring found in livers with cirrhosis is now thought to be reversible. As understanding of scar formation grows, scientists are inching closer to treatments that will help to stop scarring and heal existing liver damage.
This Nature Outline is editorially independent. It is produced with third party financial support. About this content.
This Nature Outline is editorially independent, produced with financial support from a third party. About this content.
Nature is pleased to acknowledge the financial support of the Translational Research Center for Medical Innovation (TRI), Tokyo Metropolitan Komagome Hospital, the Department of Gastroenterology and Hepatology at Yamaguchi University, OHARA Pharmaceutical Co., Ltd and PRISM BioLab. The sponsors retains sole responsibility for the following messages.
The Translational Research Center for Medical Innovation (TRI), formerly known as Translational Research Informatics Center, was founded in 2002 by the Japanese Ministry of Education, Culture, Sports, Science and Technology (MEXT) and Kobe city to promote academia-originated medical innovation. TRI established the Academic Research Organization (ARO) network in 2013, which is transforming into an Asian ARO network in conjunction with Korea, Taiwan and Singapore. We plan to expand the network globally to Europe and the United States. Our aim is to develop an infrastructure to support the launch of global clinical trials of academia-originated projects and to obtain regulatory approval worldwide.
Ohara Pharmaceutical Co., Ltd.
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
Division of Gastroenterology, Yamaguchi University School of Medicine
PRISM Pharma Co., Ltd
